Drugs / AH-008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07697560 | Jun → Sep 2026 overdue | chemotherapy-induced neuropathy | AnHorn Medicines Co. Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | AnHorn Medicines Co. Ltd. | Regulatory 【CNA News】AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation anhornmed.com ↗
The U.S. FDA IND clearance authorizes AH-008 to advance into human clinical trials, following a comprehensive review of its preclinical pharmacology, toxicology, and manufacturing data. |
| 2026-06-23 | AnHorn Medicines Co. Ltd. | Regulatory AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation anhornmed.com ↗
The U.S. FDA IND clearance authorizes AH-008 to advance into human clinical trials, following a comprehensive review of its preclinical pharmacology, toxicology, and manufacturing data. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | AnHorn Medicines Co. Ltd. | AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN) anhornmed.com ↗ |
| 2026-06-26 | AnHorn Medicines Co. Ltd. | 【CNA News】AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation anhornmed.com ↗ |
| 2026-06-23 | AnHorn Medicines Co. Ltd. | AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation anhornmed.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AH-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07697560 ↗ |
| Route | Intravenous | “AH-008 administered as a single intravenous infusion” NCT07697560 ↗ |